Status:
COMPLETED
ACE2 Gender Differences in Stroke With COVID-19
Lead Sponsor:
Fondazione Don Carlo Gnocchi Onlus
Conditions:
Neurologic Manifestations
Eligibility:
All Genders
18-90 years
Brief Summary
The new coronavirus SARS-CoV-2, causes the COVID-19 infection, which showed a form of neurovirulence involving the Central and peripheral Nervous Systems \[Baig et al, 2020\]. In a mouse model for hum...
Detailed Description
A new coronavirus was identified in December 2019 in Wuhan, China as the causative agent of "Severe Acute Respiratory Syndrome" (SARS-CoV-2), a viral lung infection indicated by the acronym COVID-19 (...
Eligibility Criteria
Inclusion
- stroke patients (hemorrhagic or ischemic) documented through Magnetic Resonance Imaging (MRI) or Computed Tomography (CT);
- NeuroCOVID19 stroke patients with double nasopharyngeal swab negative after 24 hours for SARS-Cov2.
- latency time within 6 months after stroke event;
- sufficient cognitive and language skills to understand the instructions related to the administration of the assessment scales and to sign informed consent;
Exclusion
- behavioral and cognitive disorders that may interfere with the therapeutic activity;
- other orthopaedic or neurological complications that may interfere with the rehabilitation protocol;
- inability to understand and sign informed consent;
Key Trial Info
Start Date :
September 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT04766645
Start Date
September 4 2020
End Date
January 31 2023
Last Update
July 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Don Carlo Gnocchi
Rome, Italy, 00168